BC
Brian Cheng JP Morgan Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Immunovant
IMVT
$2.87B
| $16.45 | $37 |
125%
upside
| Overweight |
12 Aug ‘25
28 days ago |
|
2
Immunome
IMNM
$761M
| $8.74 | $22 |
152%
upside
| Overweight |
7 Aug ‘25
1 month ago |
|
3
CG Oncology
CGON
$2.49B
| $32.66 | $41 |
26%
upside
| Overweight |
2 May ‘25
4 months ago |
|
4
Protagonist Therapeutics
PTGX
$3.62B
| $58.13 | $57 |
2%
downside
| Overweight |
4 Mar ‘25
6 months ago |
|
5
Intellia Therapeutics
NTLA
$1.22B
| $11.33 | $13 |
15%
upside
| Neutral |
28 Feb ‘25
6 months ago |
|
6
Zymeworks
ZYME
$1.15B
| $15.20 | $18 |
18%
upside
| Overweight |
16 Dec ‘24
8 months ago |
|
7
Xencor
XNCR
$594M
| $8.33 | $28 |
236%
upside
| Overweight |
7 Nov ‘24
10 months ago |
|
8
Kyverna Therapeutics
KYTX
$165M
| $3.81 | $33 |
766%
upside
| Overweight |
31 Jul ‘24
1 year ago |
|
9
Metagenomi
MGX
$70.2M
| $1.87 | $6 |
221%
upside
| Neutral |
2 May ‘24
1 year ago |
|
10
Mersana Therapeutics
MRSN
$35.2M
| $7.06 | $125 |
1,671%
upside
| Neutral |
19 Mar ‘24
1 year ago |
|
11
Roivant Sciences
ROIV
$9.14B
| $13.39 | $15 |
12%
upside
| Overweight |
14 Nov ‘23
1 year ago |
|
12
BioAtla
BCAB
$37.6M
| $0.6400 | $14 |
2,088%
upside
| Overweight |
25 Sep ‘23
1 year ago |
|
13
Adicet Bio
ACET
$64.1M
| $0.7700 | $6 |
679%
upside
| Neutral |
1 Jun ‘23
2 years ago |
|
|
14
Immunome
IMNM
$761M
| $8.74 | $35 |
300%
upside
| Overweight |
29 Oct ‘21
3 years ago |
|
15
Arcturus Therapeutics
ARCT
$473M
| $17.43 | $85 |
388%
upside
| Overweight |
10 Aug ‘21
4 years ago |
|
16
BioCryst Pharmaceuticals
BCRX
$1.69B
| $8.07 | $21 |
160%
upside
| Overweight |
3 Aug ‘21
4 years ago |
|
17
ADC Therapeutics
ADCT
$379M
| $3.37 | $46 |
1,265%
upside
| Overweight |
15 Jun ‘21
4 years ago |
|